



User manual for CKD-EPI eGFRcr Equation

Version 1, March 2024, in English

1. The Evidencio platform

The Evidencio platform facilitates the creation, use, validation and implementation of medical prediction models and clinical decision support tools. This user manual specifically relates to the CKD-EPI eGFRcr Equation. The User Manual can also be referred to as the Instructions For Use (IFU).

Throughout this manual CE-marked content and the term medical device are used interchangeably.

2. Disclaimer

Evidencio provides information, models, calculators, equations, and algorithms (tools) intended for use by healthcare professionals. Some of these tools have been certified as CE-medical devices. For such CE-marked content the 'Official Legal Disclaimer for CE-marked content' applies. All other content and tools provided by Evidencio are explicitly only covered by the 'Official Legal Disclaimer for non CE-marked content' both are available here: <https://www.evidencio.com/disclaimer>

3. Warnings



1. Warnings for CE-marked content

Calculations alone should never dictate patient care, and are no substitute for professional judgement.

This tool is only to be used by physicians in a clinical setting, and is not for patient use.

Always read the intended use before using this tool.


Before reading the result, double check the filled in values to prevent errors.

The result considers an estimate of Glomerular Filtration Rate, and does not guarantee a certain level of kidney functioning.

This model is only intended for use in settings where the usage and result of a model are never immediately needed.

4. Model landing page

The medical device model on the Evidencio platform is shown in Figure 1. The model landing page contains the following sections, that are indicated in Figure 1.



A. CKD-EPI eGFRcr equation

B. The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equations was developed in an effort to create a more precise formula to estimate glomerular filtrate rate (GFR) from serum creatinine and other readily available clinical parameters, especially at when actual GFR is >60 mL/min per $1.73m^2$. The CKD-EPI released their original equations in 2009, which included race as a variable. In 2021, they used the same data to derive a new equation that does not include race as an explanatory variable. This model includes the original 2009 equations, a variant of the 2009 equations not including race as a variable, and the new 2021 equations.

C. Research authors: Lesley A. Inker, M.D., Nwamaka D. Eneanya, M.D., M.P.H., Josef Coresh, M.D., Ph.D., Hcine Tighiouart, M.S., Dan Wang, M.S., Yingying Sang, M.S., Deirdra C. Crews, M.D., Alessandro Doria, M.D., Ph.D., M.P.H., Michelle M. Esprella, M.D., M.A.S., Marc Froissart, M.D., Ph.D., Morgan E. Grams, M.D., M.H.S., Ph.D., Tom Greene, Ph.D., Anders Grubb, M.D., Ph.D., Vilimundur Gudnason, M.D., Ph.D., Orlando M. Gutiérrez, M.D., Roberto Kalil, M.D., Amy B. Karger, M.D., Ph.D., Michael Maurer, M.D., Gerjan Navis, M.D., Ph.D., Robert G. Nelson, M.D., Ph.D., Emilio D. Poggio, M.D., Roger Roddy, M.D., Peter Rossing, M.D., D.M.Sc., Andrew D. Rule, M.D., Elizabeth Selvin, Ph.D., M.P.H., Jesse C. Seegmiller, Ph.D., Michael G. Shlipak, M.D., M.P.H., Vicente E. Torres, M.D., Ph.D., Wei Yang, Ph.D., Shoshana H. Ballew, Ph.D., Sara J. Couture, M.P.H., Neil R. Powe, M.D., M.P.H., M.B.A., Andrew S. Levey, M.D.
Version: 1.25

D. Draft | Nephrology | Custom model

E. LOT V-1.25-9984.24.03.05 CE 2767

F. UDI (01)008720938015083(8012)v1.25(4326)240305(240)9984

K. Download the [User manual](#) for Medical device prediction models and consult the [Intended use](#).

L. **Equation**
The CKD-EPI eGFRcr equation allows for the use of three different equations, all derived on the same population. For more information, see the additional model information

☐ 2009 CKD-EPI eGFRcr (ASR)
☐ 2009 CKD-EPI eGFRcr (ASR-NB)
☐ 2021 CKD-EPI eGFRcr (AS)

Sex
Patient sex:

Age
Patient age: years

Serum Creatinine
Serum Creatinine level in mg/dL: mg/dL

Calculate the result
This model does not calculate automatically.
Please provide all the needed parameters and press calculate.

M. Estimated GFR: ... mL/min/1.73m²
Set all parameters to calculate prediction.

The eGFR is an estimation of the Glomerular Filtration Rate, estimated through serum Creatinine concentrations.

Generally, normal GFR values lie between 90 and 120 mL/min/1.73m².
A GFR between 60 and 90 may point to early stage kidney disease
A GFR between 15 and 60 is indicative of kidney disease
a GFR below 15 is a sign of kidney failure.

One of the disadvantages of the CKD-EPI is that it only accounts for Age and Sex (and Race, in the 2009 equations) without taking into account body shape. As Creatinine is produced by muscle tissue, production levels differ between different patients, as people of the same age and gender may have drastically different amounts of muscle tissue, which influences eGFR calculation.

Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

Figure 1. An example of a model landing page.

A. Model title

This is the title and name of the model.

B. Model description

This is a short description of the model.

C. Research authors

These are the research authors of the paper that originally published the model.

D. Model tags

These are the tags that are assigned to the model. Evidencio has the following status tags: "Draft", "Public", "Private", "Under review". Evidencio has the following model type tags: "Composite model", "Sequential model", "API model". Evidencio has the following calculation method tags: "Linear model", "Logistic regression", "Cox regression", "RScript" and "Custom model". Next to this, there are tags that indicate the specialty e.g. "Cardiology".

E. LOT number

The LOT number indicated the model version, the model identifier, and the model publication date. Publication date is indicated as YY.MM.DD.

Additionally, the CE mark is displayed next to the LOT number. This way, medical devices can be easily recognized.

F. UDI number

The UDI number is an international tool that helps users identify and find information on products. UDI stands for Unique Device Identifier. Evidencio's UDIs have the following format:

(01)UDI-DI number(8012)versionnumber(4326)releasedate(240)identificationnumber

The UDI-DI number is a unique numeric code. For each medical device of Evidencio, a unique UDI-DI is ascribed. This UDI-DI is used as an "access key" for information stored in a unique device identification database (UDID). Information on Evidencio's medical devices can be found by searching for the UDI-DI number in the following data base: <https://gepir.gs1.org/index.php/search-by-gtin>

G. Details button

On the top right of the model page, several clickable buttons are displayed that show a pop-up when clicked. The first button opens a pop-up concerning additional information about the model. This pop-up has three sections: Details, Study characteristics and Supporting publications & related files.

Details

The first part of the additional information concerns the details of the model as shown in Figure 2.

Details




Model author	wrvandijk	Status	Draft
Model ID	9984	Share	  
Version	1.25		
Revision date	2024-03-05		
Specialty	Nephrology		
Model type	Custom model (Conditional)		
MeSH terms	<ul style="list-style-type: none"> Kidney Creatinine Glomerular Filtration Rate 		

Figure 2. The model details.

Study characteristics

Below the 'Details section' the section labeled 'Study characteristics' provides information on the characteristics of the patient data used to derive and validate the model. Additional information is provided on the methods used to develop and/or validate the model.

An important part of the Study characteristics is the information on Supporting publications and related files. These sections can be found at the bottom of the Details-pop-up as shown in Figure 3.

Supporting Publications

Title or description

New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race

DOI: 10.1056/NEJMoa2102953

A New Equation to Estimate Glomerular Filtration Rate

DOI: 10.7326/0003-4819-150-9-200905050-00006

Tags

External validation

Model updating

Internal validation

External validation

Internal validation

Related files

No related files available

Figure 3. An example of Supporting publications & related files.

H. Intended use button

Intended medical use

The CKD-EPI eGFRcr equation is intended to be used by professional users who are capable of operating the device and interpreting its results. It can be used to estimate the Glomerular Filtration Rate in patients to assess kidney functioning.

The device combines Age, Sex, Race, and Serum Creatinine to estimate Glomerular Filtration rate.

The device is intended to be used for patients where the Glomerular Filtration Rate should be estimated. The result of the CKD-EPI eGFRcr equation is intended to be reviewed and interpreted by qualified medical specialists only. The device is not intended for use by patients on their own.

The CKD-EPI eGFRcr equation is not intended to replace clinical decision-making, it can only provide an estimation of the patient's GFR to the user based on the serum creatinine measurement and clinical features. The user can use this information to support clinical decision-making regarding kidney dysfunction.

Clinical Benefit

Correct functioning of the CKD-EPI eGFRcr equation can result in the following clinical benefit:

- Use of the algorithm positively impacts patient management by allowing for the estimation of Glomerular Filtration Rate with a singular blood test, which estimates Renal function, informing clinical management on further *diagnostic/prognostic/therapeutic* options and strategies, and avoiding expensive, invasive or burdensome tests to measure GFR.
- Digital implementation of the algorithm underlying the CKD-EPI eGFR equation as a medical device can improve the speed and reliability of calculation.

Intended target population and exclusion

The CKD-EPI eGFRcr Equation is intended to be used only for a specific group of patients, corresponding to the below indications and contra-indications.

Clinical indication

The CKD-EPI eGFRcr Equation should be used for patients who meet the following inclusion criteria:

- 18 years or older

Contra-indications

The CKD-EPI eGFRcr equation should not be used for patients who meet the following exclusion criteria:

- Patients with Acute Kidney Injury
- Patients where Creatinine measurements were not taken with a valid calibration traceable to international standard reference material, and with minimal bias when compared to IDSM reference methodology.

The CKD-EPI eGFRcr Equation and other Creatinine based GFR estimation equations are known to sometimes perform inadequately in the following clinical populations/with the following features. Care should be taken, especially if the results do not meet expectations:

- Body composition:
 - Amputation,
 - Body Building
 - Reduced Lean Body Mass
- Diet:
 - High Protein or creatine supplements
 - Cooked meat consumption
 - Vegetarianism
- Muscle Wasting
 - Muscle wasting disease
 - Heavy Physical exercise (e.g. Marathon Running)
 - Chronic Severe Illness
- Clinical conditions:
 - Pregnancy
 - Cystic fibrosis/Cirrhosis
 - Anorexia Nervosa
 - Edematous state
 - Diabetes
 - Hyperfiltration
- Certain Medications influencing tubular secretion, or nephrotoxic drugs with a narrow window, for example:
 - Cimetidine, Trimethoprim, Fenofibrate, Dolutegravir, Tyrosine kinase inhibitors and Certain Antibiotics
- Other:
 - EGFR values exceeding anticipated values or normal physiological range
 - Very low GFR

User profile

The CKD-EPI eGFRcr equation is intended to be used by Healthcare Professionals or automatically calculated through Evidencio's API. Results shall always be reviewed and interpreted by qualified medical specialists only, in the context of the patient's clinical history and other diagnostic test results. Healthcare professionals do not require additional training prior to the use of the medical device. The device is not intended for use by patients on their own.

Intended use environment

The MDSW can be used as made available on the Evidencio platform in any actively supported web-browser on personal computers, mobile devices, or tablet PCs, and on the mobile app provided by Evidencio. The MDSW can also be used through Evidencio's iFrame representation as an embedded view, provided that the specific Evidencio guidelines for iFrame implementations of this MDSW are adhered to. Automated calculation of the device is enabled through Evidencio's API. The device is only intended for use in healthcare settings where the immediate application and outcomes of the device are not required.

Functioning, physical principle

The CKD-EPI eGFRcr equation's underlying model concerns a custom mathematical formula. The acquisition and processing of the data, the analyses to assemble the relevant criteria for the CKD-EPI eGFRcr equation as well as the setup and refinement of the CKD-EPI eGFRcr equation are described in the original study/studies from Inker et al [R1] and Levey et al [R3]. Entering the details of an individual in the web-application and pressing the Calculate button initiates the calculation of the eGFR of the patient.

I. Electronic label button

The electronic label button opens a pop-up with the location and address of Evidencio, the LOT number, the UDI number, the CE-mark, the medical device logo and a download link for the declaration of conformity of the medical device. The example of the electronic label is shown in Figure 4.

Extra Information

Intended use [Electronic label](#) [Release Notes](#)

CKD-EPI eGFRcr equation



Evidencio B.V., Irenesingel 19, 7481 GJ Haaksbergen, The Netherlands



V-1.25-9984.24.03.05



(01)008720938015083(8012)v1.25(4326)240305(240)9984



Download the [User manual](#) for Medical device prediction models



Medical device

Figure 4. Example of the electronic label

J. Release notes

The 'Release Notes' button opens a pop-up with the latest release notes of the model. Here you can find what has changed over the last versions of the model. Additionally, if there are any known residual anomalies the user should be aware of, they are listed here.

K. User Manual

This user manual can be found in three places: 1) under the short description, 2) on the right of the model page, and 3) in the electronic label. Additionally, all versions of the user manual can be found in the general page for all user manuals for medical devices. The page can be found under the 'About' drop-down menu button as shown in Figure 5. The user manual page is shown in Figure 6.




Figure 5. The drop-down menu where the user manual page can be found.




Figure 6. The user manual page for all user manuals.

You (The user) can always print this downloaded manual. When necessary, you can request a paper version of the manual to be sent to you by mail. Evidencio's contact details are listed in Chapter 6 of this user manual.

L. Input section

The Evidencio platform allows two separate input variables; categorical, and continuous variables.

Categorical variables

In the example shown in Figures 7 and 8, the **Sex** variable concerns a categorical variable. The version that is wished to be used can be entered by clicking on either button. The selected button changes to green, as seen in Figure 8.



Figure 7. The variable for Sex, where no button has been clicked, and thus no input has been provided by the user.



Figure 8. The variable for Sex version, where the “Male” button has been clicked.

Similarly, in Figure 9, a list-based categorical variable is shown




Figure 9. The variable Equation, where the “2009 CKD-EPI eGFRcr (ASR)” button has been clicked

Continuous variables

In the example shown in Figure 9, the **Serum Creatinine** variable, exemplifies a continuous variable. The plausible ranges for the variables are used for the model.

The details for a patient can be entered by sliding the button to the correct value, or by entering the correct value in the box on the right-hand side (i.e., where the 20 is entered for **Serum Creatinine**).



Figure 10. The variable for Serum Creatinine, where “20” has been entered

Details on variable measurements

Directly underneath the name for each variable, additional details can be provided on the methods required to enter the correct value for each variable. In Figure 9, the details below **Equation** explain what the options that can be selected are.

M. Result section

At the bottom of the page, the results of the model are shown.

Result calculation

When all variables are filled in, a result will be calculated. No risk is displayed until all variables are filled in. The result section indicates “Set all parameters to calculate prediction.”

Result interpretation

In the result interpretation, a risk stratification is given based on the risk score. An example of the information is shown in Figure 11.

Estimated GFR: **2.43** ml/min/1.73m²

Conditional information

eGFR below 15ml/min/1.73m² correspond to the following KDIGO GFR category

G5: Kidney Failure

The eGFR is an estimation of the Glomerular Filtration Rate, estimated through serum Creatinine concentrations.

Generally, normal GFR values lie between 90 and 120 ml/min/1.73m².

A GFR between 60 and 90 may point to early stage kidney disease

A GFR between 15 and 60 is indicative of kidney disease

a GFR below 15 is a sign of kidney failure.

One of the disadvantages of the CKD-EPI is that it only accounts for Age and Sex (and Race, in the 2009 equations) without taking into account body shape. As Creatinine is produced by muscle tissue, production levels differ between different patients, as people of the same age and gender may have drastically different amounts of muscle tissue, which influences eGFR calculation.

Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

Figure 11. The result information

Relevant information for correct use of the model

At the bottom of the page, there is a link to Evidencio's terms and conditions of use, the privacy policy, and the disclaimer.

5. Use of Medical devices

In general, and unless explicitly stated otherwise, CE-marked tools on Evidencio are only to be used by physicians in a clinical setting, and are not for patient use.

To use the tool, Evidencio requires a stable internet connection and runs on the following devices:

- Personal computers or laptops using the following browsers:
 - Safari (the latest three versions)
 - Chrome (the latest three versions)
 - Firefox (the latest three versions)
 - Edge (the latest three versions)
- Tablets or smartphones running on the next operating systems:
 - IOS (the latest three versions)
 - Android (the latest three versions)

The medical device cannot be used in combination with Internet Explorer. The personal computers, laptops, tablets or smartphones used should at least be able to have an internet connection and use the browsers mentioned above. The minimal screen resolution should be 800x600.

Furthermore, the model may be used through the Evidencio iFrame representation of the calculator, as an embedded view, provided that the specific Evidencio guidelines for iFrame implementations of that model are adhered to.

The Evidencio SaMD models can be used with any browser settings that don't distort the regular display of websites, with a 50% to 500% zoom rate, and at a display resolution starting from 800x600. However, factory recommended browser settings, 100% zoom rate and regular display resolution are recommended.

This model is only intended for use in settings where the usage and result of a model are never immediately needed.

6. Manufacturer details

Any serious incident that has occurred in relation to the device should be reported to the manufacturer and the competent authority of the country in which you, the reader, are established. A competent authority is the institute that governs all issues related to medical devices in a country.

Contact details of your competent authority can be found here: <https://www.ema.europa.eu/en/partners-networks/eu-partners/eu-member-states/national-competent-authorities-human>

Please contact Evidencio when you suspect any malfunction or changes in the performance of a medical device. Do not use the device, until Evidencio replies to your message that it is safe to start using it again.

Contact details of Evidencio:



Evidencio B.V., Irenesingel 19, 7481 GJ Haaksbergen, The Netherlands
www.evidencio.com
tel: +31 53 85195 08
e-mail: info@evidencio.com